Menu
FDA DECISION ·
Tecvayli + Darzalex Faspro
teclistamab-cqyv with daratumumab and hyaluronidase-fihj · Janssen Biotech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory multiple myeloma after at least one prior line containing a proteasome inhibitor and an immunomodulatory drug.
SUPPORTING DATA
Evidence behind the decision
- Study
- MajesTEC-3 randomized 587 patients to teclistamab plus subcutaneous daratumumab or investigator choice of two active daratumumab regimens.
- Key result
- Median progression-free survival was unreached versus 18.1 months (hazard ratio 0.17, 95% CI, 0.12–0.23).
- Safety to report
- FDA describes boxed warnings for cytokine release syndrome and neurologic toxicity. Review the current REMS and infection precautions.
- Evidence limits
- The result compares the combination with DPd or DVd. It cannot be attributed to teclistamab monotherapy in a different treatment line.
LAMPGEN ANALYSIS
Why it matters
The approval moves a BCMA-directed bispecific combination into earlier relapsed disease. MajesTEC-3 evaluated the combination against active daratumumab regimens.
What research teams should watch
Sites need step-up dosing readiness, CRS and neurologic toxicity escalation, infection surveillance and familiarity with the current REMS requirements.
Clinical operations takeaway
Ask monitors to describe how they would verify site readiness, document safety follow-up, and escalate an unresolved finding under the study plan. Make those responsibilities part of the monitoring brief.
Explore oncology CRA staffingRelated study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
Relapsed or refractory multiple myelomaPRIMARY RECORDS